Bayer’s antibiotic drug-device combo fails in late-stage trial

Bayer (ETR:BAYN) reported last week that its antibiotic drug-device combination product failed in a phase III trial.

In the 725-patient Inhale trial, Bayer’s Amikacin Inhale did not out-perform a placebo as a treatment for Gram-negative pneumonia in patients on ventilators.

Get the full story at our sister site, Drug Delivery Business News.

The post Bayer’s antibiotic drug-device combo fails in late-stage trial appeared first on MassDevice.

from MassDevice http://ift.tt/2n70sBy